To further validate whether CASP-8 modulates the anti-myeloma activity of Len in primary cells, we cultured CD138+ primary myeloma cells from bone marrow of two patients and treated them with CASP-8 inhibitor z-IETD-fmk and/or Len. This evidence concerns the gene SDC1 and plasma cell myeloma.